SOPHiA GENETICS technology to aid research
associated with hereditary cancers and disorders
BOSTON and LAUSANNE, Switzerland, June 22,
2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company in the healthcare space and a
leader in data-driven medicine, today announced that Ankara
Etlik City Hospital, the largest hospital in the capital city of
Turkey, is live on the SOPHiA DDM™
Platform. The hospital, which opened its doors in September 2022 and serves roughly 15,000 patients
daily, will utilize multiple SOPHiA GENETICS solutions to
streamline genomic testing, specifically associated with hereditary
disorders.
"Since opening our doors eight months ago, we've seen more than
two million patients," said Dr. Taha Bahsi, Head of Medical
Genetics, Ankara Etlik City Hospital. "We are investing in
technologies like SOPHiA DDM™ to best serve our community. The
SOPHiA GENETICS technology will help create efficiencies in the
analysis of genomic profiles and the identification of variants
often associated with hereditary disorders such as cancers."
Hereditary cancer is responsible for roughly one in 10 diagnosed
cancers[1]. Next-generation sequencing (NGS), is commonly used in
the detection of biomarkers for hereditary cancers but produces a
vast and complex data set that is timely for researchers to
analyze. Using an array of sophisticated algorithms, the SOPHiA
DDM™ Platform helps to streamline and expedite data analysis, which
will save valuable time for clinical researchers. In addition, the
tailored NGS-based workflows empower researchers to obtain
high-quality, reproducible data that helps accelerate cancer
research, including testing for new and existing therapies.
"The SOPHiA DDM™ Platform offers multiple applications paired
with sophisticated algorithms that allow organizations such as
Ankara Etlik City Hospital to increase the volume of research and
testing," said Abhimanyu Verma,
Chief Technology Officer, SOPHiA
GENETICS. "Our platform connects data points from
institutions globally, allowing Ankara Etlik City Hospital's
researchers to expedite the analysis of genomic profiles and draw
further insights that their teams can leverage to better care for
the millions of people in and around the capital city of
Ankara."
Ankara Etlik City Hospital has implemented SOPHiA DDM™
applications that will create a streamlined workflow to help
accelerate research and will enable Ankara Etlik City Hospital
to develop an in-house database of genomic data and insights. This
database will help to create efficiencies with research and support
experts as they work to make data-driven decisions.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook,
and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains
statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products, and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management's beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
[1]
https://www.cancer.gov/about-cancer/causes-prevention/genetics#:~:text=Up%20to%2010%25%20of%20all,of%20getting%20cancer%20is%20increased.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ankara-etlik-city-hospital-is-live-on-sophia-genetics-platform-301857500.html
SOURCE SOPHiA GENETICS